498 related articles for article (PubMed ID: 18037413)
1. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
[TBL] [Abstract][Full Text] [Related]
2. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
3. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
Dreyfus F
Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
[TBL] [Abstract][Full Text] [Related]
4. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
5. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.
Wells RA; Leber B; Buckstein R; Lipton JH; Hasegawa W; Grewal K; Yee K; Olney HJ; Larratt L; Vickars L; Tinmouth A
Leuk Res; 2008 Sep; 32(9):1338-53. PubMed ID: 18405971
[TBL] [Abstract][Full Text] [Related]
6. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Rose C; Brechignac S; Vassilief D; Pascal L; Stamatoullas A; Guerci A; Larbaa D; Dreyfus F; Beyne-Rauzy O; Chaury MP; Roy L; Cheze S; Morel P; Fenaux P;
Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
[TBL] [Abstract][Full Text] [Related]
7. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Goldberg SL
Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
[TBL] [Abstract][Full Text] [Related]
8. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.
Mittelman M; Lugassy G; Merkel D; Tamary H; Sarid N; Rachmilewitz E; Hershko C; ;
Isr Med Assoc J; 2008 May; 10(5):374-6. PubMed ID: 18605364
[No Abstract] [Full Text] [Related]
9. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
Malcovati L
Leuk Res; 2007 Dec; 31 Suppl 3():S2-6. PubMed ID: 18037415
[TBL] [Abstract][Full Text] [Related]
10. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
12. Iron chelation therapy for patients with myelodysplastic syndrome.
Yeh SP; Yang YS; Yao CY; Peng CT
Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
[TBL] [Abstract][Full Text] [Related]
13. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
Chacko J; Pennell DJ; Tanner MA; Hamblin TJ; Wonke B; Levy T; Thomas PW; Killick SB
Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
[TBL] [Abstract][Full Text] [Related]
14. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
[TBL] [Abstract][Full Text] [Related]
15. Controversies surrounding iron chelation therapy for MDS.
Leitch HA
Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
[TBL] [Abstract][Full Text] [Related]
16. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Int J Hematol; 2008 Jul; 88(1):24-29. PubMed ID: 18581200
[TBL] [Abstract][Full Text] [Related]
17. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Malcovati L
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
[TBL] [Abstract][Full Text] [Related]
18. [The role of iron metabolism in myelodysplastic syndromes].
Finelli C; Clissa C; Stanzani M
Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
[TBL] [Abstract][Full Text] [Related]
19. Impact of iron overload in myelodysplastic syndromes.
Fenaux P; Rose C
Blood Rev; 2009 Dec; 23 Suppl 1():S15-9. PubMed ID: 20116635
[TBL] [Abstract][Full Text] [Related]
20. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.
Neukirchen J; Fox F; Kündgen A; Nachtkamp K; Strupp C; Haas R; Germing U; Gattermann N
Leuk Res; 2012 Aug; 36(8):1067-70. PubMed ID: 22564985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
